BioCentury | Dec 20, 2019
Clinical News

Stealth cites endpoints in Phase III mitochondrial disease miss

...“Deal Streak Continues for Alexion as Achillion’s Story Hits $930M High Note” ). Lauren Martz, Associate Editor Subcutaneous elamipretide...
BioCentury | Oct 11, 2019
Company News

Alexion deal lends late-stage support to Stealth

...an option to license exclusive ex-U.S. rights as well as rights to co-promote and develop subcutaneous elamipretide...
...of the Milken Institute dedicated to speeding up and improving medical research. Elizabeth S. Eaton, Staff Writer Subcutaneous elamipretide...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Technologies Ltd. (NASDAQ:SLGL) TWIN (S6G5T) Treat acne Phase III data 4Q19 Stealth BioTherapeutics Corp. (NASDAQ:MITO) Subcutaneous elamipretide...
BioCentury | Dec 30, 2018
Financial News

Months after Hong Kong proposal, Stealth now seeking NASDAQ listing

...solution 1% (MTP-131, bendavia, ocuvia, ss-31) IV elamipretide (MTP-131, bendavia, ocuvia, ss-31) Oral elamipretide (MTP-131, bendavia, ocuvia, ss-31) Subcutaneous elamipretide...
BioCentury | Jun 22, 2018
Financial News

Stealth to start Phase IIb of AMD candidate with $100M financing

...Stealth's board. Stealth BioTherapeutics Inc., Newton, Mass. Elizabeth S. Eaton elamipretide ophthalmic solution 1% (MTP-131, bendavia, ocuvia, ss-31) Subcutaneous elamipretide...
BioCentury | Aug 10, 2017
Clinical News

Stealth begins Phase II/III of elamipretide in Barth syndrome

...BioTherapeutics Inc. (Newton, Mass.) began the double-blind, crossover, U.S. Phase II/III TAZPOWER trial to evaluate subcutaneous elamipretide...
...cardiolipin to promote electron transfer and prevent apoptosis. Stealth BioTherapeutics Inc. , Newton, Mass. Product: Subcutaneous elamipretide...
...patient-reported outcomes, Clinician Global Impression (CGI) scale and biomarkers Status: Phase II/III started Milestone: NA Alex Himes subcutaneous elamipretide Stealth...
BioCentury | Jul 13, 2017
Clinical News

Stealth reports Phase II extension trial data of elamipretide in mitochondrial myopathy

...primary mitochondrial myopathy in the Phase II MMPOWER-2 extension trial showing that once-daily 40 mg subcutaneous elamipretide...
...cardiolipin to promote electron transfer and prevent apoptosis. Stealth BioTherapeutics Inc. , Newton, Mass. Product: Subcutaneous elamipretide...
...Fatigue Questionnaire, Patient Global Assessment and Physician Global Assessment Status: Phase II data Milestone: NA Julian Zhu subcutaneous elamipretide Stealth...
BioCentury | Nov 15, 2016
Clinical News

Subcutaneous elamipretide: Ph I started

...Stealth began the open-label, U.S. Phase I ReCLAIM trial to evaluate 40 mg subcutaneous elamipretide once daily...
...12 weeks in about 40 patients ages ≥55. Stealth BioTherapeutics Inc. , Newton, Mass. Product: Subcutaneous elamipretide...
...ophthalmic examinations from baseline and feasibility Status: Phase I started Milestone: Phase I data (mid-2017) Julian Zhu MTP-131 subcutaneous elamipretide Stealth...
BioCentury | Jul 11, 2016
Clinical News

Subcutaneous elamipretide: Phase II started

...began the double-blind, placebo-controlled, European Phase II PROGRESS-HF trial to evaluate 4 and 40 mg subcutaneous elamipretide...
...daily for 28 days in about 45 patients. Stealth BioTherapeutics Inc. , Newton, Mass. Product: Subcutaneous elamipretide...
BioCentury | Jul 11, 2016
Clinical News

Subcutaneous elamipretide: Phase II started

...Stealth began the double-blind, placebo-controlled, European Phase II RESTORE-HF trial to evaluate 40 mg subcutaneous elamipretide once...
...daily for 28 days in about 46 patients. Stealth BioTherapeutics Inc. , Newton, Mass. Product: Subcutaneous elamipretide...
Items per page:
1 - 10 of 10